IDXX Stock Overview Develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More details
Rewards Risk Analysis IDXX passed our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
IDEXX Laboratories, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for IDEXX Laboratories Historical stock prices Current Share Price US$399.60 52 Week High US$535.60 52 Week Low US$374.80 Beta 1.37 1 Month Change -0.62% 3 Month Change -11.96% 1 Year Change -20.59% 3 Year Change -30.04% 5 Year Change 70.04% Change since IPO 175.30%
Recent News & Updates
Insufficient new directors Dec 19
IDEXX Laboratories, Inc. to Report Q4, 2024 Results on Feb 03, 2025 Dec 12
Insufficient new directors Nov 29
IDEXX Laboratories, Inc. Announces Chief Financial Officer Changes Nov 22 IDEXX Laboratories, Inc. Announces Chief Financial Officer Changes
Third quarter 2024 earnings released: EPS: US$2.83 (vs US$2.55 in 3Q 2023) Nov 01 See more updates
Insufficient new directors Dec 19
IDEXX Laboratories, Inc. to Report Q4, 2024 Results on Feb 03, 2025 Dec 12
Insufficient new directors Nov 29
IDEXX Laboratories, Inc. Announces Chief Financial Officer Changes Nov 22 IDEXX Laboratories, Inc. Announces Chief Financial Officer Changes
Third quarter 2024 earnings released: EPS: US$2.83 (vs US$2.55 in 3Q 2023) Nov 01
IDEXX Laboratories, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Aug 08
Second quarter 2024 earnings released: EPS: US$2.46 (vs US$2.70 in 2Q 2023) Aug 07
IDEXX Laboratories, Inc. Revises Earnings Guidance for the Year 2024 Aug 06
IDEXX Laboratories, Inc. to Report Q2, 2024 Results on Aug 06, 2024 May 05
IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024 May 03
First quarter 2024 earnings released: EPS: US$2.84 (vs US$2.58 in 1Q 2023) May 02
Idexx Laboratories, Inc. Revises Earnings Guidance for 2024 May 01
Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022) Feb 25
Idexx Launches Vellotm, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect Feb 15
IDEXX Laboratories, Inc. to Report Q1, 2024 Results on May 02, 2024 Feb 07
IDEXX Laboratories, Inc. Provides Financial Guidance for 2024 Feb 06
Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022) Feb 05
Now 27% overvalued after recent price rise Feb 05
New major risk - Share price stability Jan 17
IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024 Dec 08
Insufficient new directors Dec 01
IDEXX Laboratories, Inc. Expands Snap Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-Borne Diseases Nov 09
New minor risk - Share price stability Nov 04
Third quarter 2023 earnings released: EPS: US$2.55 (vs US$2.17 in 3Q 2022) Nov 02
IDEXX Laboratories, Inc. Provides Financial Guidance for 2023 Nov 02
IDEXX Laboratories, Inc. to Report Q4, 2023 Results on Feb 05, 2024 Nov 01
Executive VP & Chief Commercial Officer recently sold €2.8m worth of stock Sep 03
IDEXX Laboratories, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Aug 03
IDEXX Laboratories, Inc. Provides Earnings Guidance for the Fiscal Year 2023 Aug 02
Second quarter 2023 earnings released: EPS: US$2.70 (vs US$1.57 in 2Q 2022) Aug 02
IDEXX Laboratories, Inc. Announces the Election of Irene Chang Britt as an Independent Class I Director and as an Independent Member of Audit Committee and Compensation and Talent Committee Jul 13
IDEXX Laboratories, Inc. Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio Jun 16
Independent Director recently sold €862k worth of stock May 09
First quarter 2023 earnings released: EPS: US$2.58 (vs US$2.30 in 1Q 2022) May 03 IDEXX Laboratories, Inc. to Report Q1, 2023 Results on May 02, 2023
Full year 2022 earnings released: EPS: US$8.12 (vs US$8.74 in FY 2021) Feb 07
IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2023 Feb 07
Insufficient new directors Nov 16
IDEXX Laboratories, Inc. to Report Q4, 2022 Results on Feb 06, 2023 Nov 04
Third quarter 2022 earnings released: EPS: US$2.17 (vs US$2.06 in 3Q 2021) Nov 02
Insufficient new directors Nov 02
IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2022 Nov 02
Second quarter 2022 earnings released: EPS: US$1.57 (vs US$2.37 in 2Q 2021) Aug 03
IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022 Aug 03
Investor sentiment deteriorated over the past week May 11
IDEXX Laboratories, Inc. to Report Q2, 2022 Results on Aug 02, 2022 May 07
First quarter 2022 earnings released: EPS: US$2.30 (vs US$2.39 in 1Q 2021) May 05 IDEXX Laboratories, Inc., Annual General Meeting, May 11, 2022
IDEXX Laboratories, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 12
Senior Advisor & Director recently sold €112k worth of stock Feb 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 03
IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022 Feb 03
IDEXX Laboratories, Inc. Announces Series of Product and Service Enhancements That Enable Veterinary Practices to Be More Efficient While Managing Increasing Patient Volumes Jan 14
Investor sentiment deteriorated over the past week Jan 07
Executive VP & Chief Commercial Officer recently sold €2.6m worth of stock Dec 03
Third quarter 2021 earnings released: EPS US$2.06 (vs US$1.71 in 3Q 2020) Nov 03
President recently sold €3.4m worth of stock Aug 18
Insider recently sold €6.0m worth of stock Aug 07
Second quarter 2021 earnings released: EPS US$2.37 (vs US$1.75 in 2Q 2020) Jul 31
IDEXX Laboratories, Inc.(NasdaqGS:IDXX) dropped from Russell 1000 Dynamic Index Jun 27
IDEXX Laboratories, Inc. (NasdaqGS:IDXX) acquired ezyVet. Jun 03
Chief Marketing Officer & Senior VP recently sold €916k worth of stock Jun 03
Chief Marketing Officer & Senior VP recently sold €1.3m worth of stock May 26
Independent Director has left the company May 20
Senior Advisor & Director recently sold €227k worth of stock May 13
First quarter 2021 earnings released: EPS US$2.39 (vs US$1.31 in 1Q 2020) May 05
IDEXX Laboratories, Inc. Raises Earnings Guidance for 2021 May 05
Independent Director recently sold €135k worth of stock Feb 19
New 90-day high: €452 Feb 19 Dr. Rebecca M. Henderson Intends to Retire from the Board of Directors of IDEXX Laboratories, Inc
Independent Director recently sold €4.9m worth of stock Feb 10
Full year 2020 earnings released: EPS US$6.82 (vs US$4.97 in FY 2019) Feb 04
Revenue beats expectations Feb 04
New 90-day high: €424 Feb 03
IDEXX Laboratories, Inc. and the Tuskegee University College of Veterinary Medicine Announce Initiative Jan 29
IDEXX Laboratories, Inc. to Report Q4, 2020 Results on Feb 02, 2021 Jan 12
Idexx Laboratories, Inc. Elects Asha S. Collins as an Independent Class I Director Nov 13
Senior Advisor & Director recently sold €7.6m worth of stock Nov 05
Third-quarter earnings released: Revenue beats expectations Oct 30
Third quarter earnings released Oct 30
New 90-day high: €370 Oct 29
New 90-day high: €353 Oct 12
IDEXX Laboratories, Inc. to Report Q3, 2020 Results on Oct 29, 2020 Oct 07
Independent Director recently sold €355.0k worth of stock Aug 20
IDEXX Laboratories, Inc. to Report Q2, 2020 Results on Jul 31, 2020 Jul 21 Shareholder Returns IDXX AT Medical Equipment AT Market 7D -3.4% -1.4% -1.4% 1Y -20.6% 5.4% -1.6%
See full shareholder returns
Return vs Market: IDXX underperformed the Austrian Market which returned -1.6% over the past year.
Price Volatility Is IDXX's price volatile compared to industry and market? IDXX volatility IDXX Average Weekly Movement 3.9% Medical Equipment Industry Average Movement 6.1% Market Average Movement 3.8% 10% most volatile stocks in AT Market 6.2% 10% least volatile stocks in AT Market 2.1%
Stable Share Price: IDXX has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: IDXX's weekly volatility (4%) has been stable over the past year.
About the Company IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community.
Show more IDEXX Laboratories, Inc. Fundamentals Summary How do IDEXX Laboratories's earnings and revenue compare to its market cap? IDXX fundamental statistics Market cap €32.35b Earnings (TTM ) €830.20m Revenue (TTM ) €3.68b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IDXX income statement (TTM ) Revenue US$3.84b Cost of Revenue US$1.51b Gross Profit US$2.33b Other Expenses US$1.47b Earnings US$866.24m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 03, 2025
Earnings per share (EPS) 10.58 Gross Margin 60.72% Net Profit Margin 22.53% Debt/Equity Ratio 54.0%
How did IDXX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 01:58 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources IDEXX Laboratories, Inc. is covered by 31 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Daniel Owczarski Avondale Partners Ishan Majumdar Baptista Research Balaji Prasad Barclays
Show 28 more analysts 
